Apert p.Ser252Trp mutation in FGFR2 alters osteogenic potential and gene expression of cranial periosteal cells.
Apert syndrome (AS), a severe form of craniosynostosis, is caused by dominant gain-of-function mutations in FGFR2. Because the periosteum contribution to AS cranial pathophysiology is unknown, we tested the osteogenic potential of AS periosteal cells (p.Ser252Trp mutation) and observed that these cells are more committed toward the osteoblast lineage. To delineate the gene expression profile involved in this abnormal behavior, we performed a global gene expression analysis of coronal suture periosteal cells from seven AS patients (p.Ser252Trp), and matched controls. We identified 263 genes with significantly altered expression in AS samples (118 upregulated, 145 downregulated; SNR >or= |0.4|, P <or= 0.05). Several upregulated genes are involved in positive regulation of cell proliferation and nucleotide metabolism, whereas several downregulated genes are involved in inhibition of cell proliferation, gene expression regulation, cell adhesion, and extracellular matrix organization, and in PIK3-MAPK cascades. AS expression profile was confirmed through real-time PCR of a selected set of genes using RNAs from AS and control cells as well as from control cells treated with high FGF2 concentration, and through the analysis of genes involved in FGF-FGFR signaling. Our results allowed us to: (a) suggest that AS periosteal cells present enhanced osteogenic potential, (b) unravel a specific gene expression signature characteristic of AS periosteal cells which may be associated with their osteogenic commitment, (c) identify a set of novel genes involved in the pathophysiology of AS or other craniosynostotic conditions, and (d) suggest for the first time that the periosteum might be involved in the pathophysiology of AS.
Fanganiello
Roberto D
RD
Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, Brazil.
Sertié
Andréa L
AL
Reis
Eduardo M
EM
Yeh
Erika
E
Oliveira
Nélio A J
NA
Bueno
Daniela F
DF
Kerkis
Irina
I
Alonso
Nivaldo
N
Cavalheiro
Sérgio
S
Matsushita
Hamilton
H
Freitas
Renato
R
Verjovski-Almeida
Sergio
S
Passos-Bueno
Maria Rita
MR
D000168:Acrocephalosyndactylia / Q000235:genetics* / Q000473:pathology*; D000293:Adolescent; D019943:Amino Acid Substitution / Q000235:genetics; D002454:Cell Differentiation / Q000235:genetics; D019070:Cell Lineage / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D005260:Female; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology; D015870:Gene Expression; D020869:Gene Expression Profiling; D018507:Gene Expression Regulation, Developmental; D006801:Humans; D007223:Infant; D008297:Male; D009154:Mutation; D020411:Oligonucleotide Array Sequence Analysis; D010012:Osteogenesis / Q000235:genetics*; D010521:Periosteum / Q000378:metabolism* / Q000473:pathology*; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000235:genetics*; D012694:Serine / Q000737:chemistry / Q000235:genetics; D012886:Skull / Q000166:cytology; D014364:Tryptophan / Q000737:chemistry / Q000235:genetics
D012694:Serine; D014364:Tryptophan; D051497:Receptor, Fibroblast Growth Factor, Type 2